Reports Q4 revenue $217.3M, consensus $215.55M. "We delivered another strong year in 2022, helping a record number of patients with their care," said Steve Chapman, Natera’s Chief Executive Officer. "We achieved important milestones that demonstrate the clinical utility of our tests, expanded coverage, and built on our leadership in evidence generation. Our guidance for 2023 reflects our expectations for robust top-line growth as we reduce operating expenses and continue to position the company for ongoing success."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NTRA:
- Personalis price target lowered to $5 from $11 at Morgan Stanley
- Natera price target raised to $80 from $70 at Piper Sandler
- New paper highlights clinical utility of Natera’s Renasight in kidney disease
- Raymond James Sees ‘Multiple Expansion’ to Drive Stock Market Returns — Here Are 2 Stocks to Play That Bullish Sentiment
- Natera announces new data on MRD test to be presented at ASCO GI 2023